BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ProImmune Limited Services for Measuring Cell-Mediated Immune Responses Are Now Available In Formal Compliance with GLP and GCP


10/21/2010 1:01:07 PM

Oxford, UK, 21st October 2010, ProImmune Ltd., a leading provider of services for epitope discovery and immunogenicity risk assessment, announced today that its assay services for measuring cell mediated immune responses, including ELISpot assays, are now available in accordance with GLP and GCP.

Assays for measuring cellular immune responses help address key questions in the development of biological therapies. However, pharmaceutical companies often have difficulties integrating these assays into their preclinical and clinical development processes while complying with GLP and GCP. Outsourcing cellular assays to a dedicated facility working to GLP and GCP standards overcomes this problem, ensures data fully meet the requirements of regulatory submission and saves the cost and effort of setting up these time-consuming assays in-house.

Dr. Nikolai Schwabe, CEO of ProImmune, said: “Complying formally with GLP and GCP standards addresses an unmet need for many developers of novel therapies. It also demonstrates ProImmune’s commitment to supporting our customers’ requirement for understanding and characterizing immune response in all phases of pharmaceutical product development.”

About ProImmune - www.proimmune.com ProImmune is a private biotechnology company that specializes in providing products and services for epitope discovery, immune monitoring and the design of biological drugs with reduced immunogenicity risk. ProImmune has a wide range of customers, including leading pharmaceutical and biotechnology companies, as well as clinical and academic research institutes throughout the world.

For more information, please contact At ProImmune: Dr Nikolai Schwabe, CEO Tel: +44 (0) 870 042 7279 Email: enquiries@proimmune.com

Media enquiries: College Hill Life Sciences Adam Michael and Jayne Crook Tel: +44 (0)207 866 7862 Email: jayne.crook@collegehill.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES